Business
Issue of Equity and Total Voting Rights
Issue of Equity and Total Voting Rights.
About this update from Niox Group Plc
[{"type":"text","content":"\n \nRNS Number : 0578V Circassia Pharmaceuticals Plc 18 July 2018 \n\n 18 July 2018\nCircassia Pharmaceuticals plc\n \nIssue of Equity and Total Voting Rights\n \nCircassia Pharmaceuticals plc (\"Circassia\" or \"the Company\") (LSE: CIR) announces that, further to the announcement made on 16th July 2018, 23,725,800 Ordinary Shares have been admitted to the premium listing segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange's main market for listed securities (together, \"Admission\").\n \nIn accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, Circassia confirms that the Company's issued share capital consists of 357,192,062 Ordinary Shares, each with equal voting rights. No shares are held in treasury.\n \nThe above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.\n \nFor further information, please contact:\n \nCircassia Pharmaceuticals plc\n \nJulien Cotta, Company Secretary +44 (0) 1865 405560\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END MSCEAAXPFSFPEFF\n ","length":2621,"tagName":"div"}]